Drug Development Pipeline
Burlulipase is a liquid solution developed to treat pancreatic insufficiency caused by CF. It is a bacterial lipase that has been shown to be more resistant against inactivation by gastric acid, giving the drug the potential to be more effective than existing pancreatin products derived from pigs.
A phase two trial was completed in people with CF ages 12 and older. No further clinical development in CF is planned at this time.
This program was sponsored by Nordmark Pharmaceuticals and conducted within the Therapeutics Development Network.
This program is no longer being pursued by Nordmark Pharmaceuticals.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More